Results 251 to 260 of about 265,886 (307)

Local immunotherapy for the treatment of cancer: scientific advances and clinical potential. [PDF]

J Immunother Cancer
Kaufman HL, de Gruijl TD.
europepmc   +1 more source

Neoadjuvant Therapy

Annals of Surgery, 1999
openaire   +2 more sources

Risk factors for distant recurrence in patients with rectal cancer supporting selection for total neoadjuvant therapy. [PDF]

Acta Oncol
Slipsager AB, Bahij R, Christensen HS, Diness LV, Havelund BM, Ramlov A, Skriver SK, Szpejewska JE, Tcacenco O, Thomsen C, Poulsen LØ.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Neoadjuvant Therapy for Melanoma

Surgical Oncology Clinics of North America, 2020
With the universal adoption of immune checkpoint blockade and agents targeting BRAF-mutated melanomas in the metastatic setting, numerous clinical trials have evaluated these agents in the neoadjuvant setting. These smaller trials have shown promising results with high pathologic response rates and acceptable safety.
Michael C, Lowe, Ragini R, Kudchadkar
openaire   +2 more sources

Neoadjuvant Chemoradiotherapy and Neoadjuvant Chemotherapy

2017
Rectal cancer is a challenging disease to treat, and its optimal management requires a multidisciplinary approach with involvement of surgical, medical, and radiation oncologists.
Mohamed E. Salem, John L. Marshall
openaire   +1 more source

Neoadjuvant Aortic Endografting

Annals of Vascular Surgery, 2009
The advent and success of endovascular repair of abdominal aneurysms led to the development of catheter-based techniques to treat thoracic aortic pathology. Such diseases, including thoracic aortic aneurysms, acute and chronic type B dissections, penetrating aortic ulcers, and traumatic aortic transection, challenge surgeons to perform complex open ...
G, Roche-Nagle, M, de Perrot, T K, Waddell, G, Oreopoulos, B B, Rubin   +4 more
openaire   +2 more sources

Neoadjuvant Chemoimmunotherapy

Thoracic Surgery Clinics
Neoadjuvant treatment strategies for early-stage resectable non-small cell lung cancer (NSCLC) are evolving with the introduction of immune checkpoint inhibitors. While traditional neoadjuvant chemotherapy has offered modest survival benefit, recent trials show that combining chemotherapy with immunotherapy significantly increases pathologic complete ...
Gökce, Yavuz, Jonathan D, Spicer
openaire   +2 more sources

Neoadjuvant Chemotherapy for Osteosarcoma of the Extremity

Clinical Orthopaedics and Related Research, 1987
Eighty-five patients with nonmetastatic, high-grade osteosarcoma of an extremity received intravenous methotrexate and intraarterial cisplatinum and then a definitive surgical resection. The preliminary results suggest that preoperative chemotherapy with a delayed surgical resection is as safe as immediate surgery. More patients are candidates for limb
BACCI G, SPRINGFIELD D, CAPANNA, RODOLFO, PICCI P, GUERRA A, ALBISINNI U, RUGGIERI P, BIAGINI R, CAMPANACCI M.   +8 more
openaire   +3 more sources

Biomarkers in Neoadjuvant Trials

2008
Neoadjuvant chemotherapy trials have consistently reported lower response rates in patients with hormone receptor-positive (HR+) breast cancers when compared with hormone receptor-negative (HR ) tumors. There are now many pharmacologic agents on the market for both the treatment and the prevention of breast cancer, while even more agents are being ...
Regina M, Fearmonti, Khandan, Keyomarsi, Kelly K, Hunt   +2 more
openaire   +2 more sources